| 钟奕伟,吕晓鸣,石妍,黄明伟,郑磊,刘树铭,郭传瑸,张建国.125I粒子治疗儿少期头颈部交界瘤的靶区与剂量设计[J].中华放射医学与防护杂志,2022,42(2):110-114 |
| 125I粒子治疗儿少期头颈部交界瘤的靶区与剂量设计 |
| Target and dose design of 125I seed brachytherapy for treatment of pediatric borderline tumor in head neck region |
| 投稿时间：2021-11-17 |
| DOI：10.3760/cma.j.cn112271-20211117-00454 |
| 中文关键词: 近距离治疗 头颈部交界性肿瘤 儿少期 剂量学 |
| 英文关键词:Brachytherapy Head and neck borderline tumor Pediatric Dosimetry |
| 基金项目:国家自然科学基金（81302387）；广东省职业病防治重点实验室（2017B030314152）；广东省自然科学基金（2019A1515011969）；广东省医学科研基金项目（A2017227，A2019246，A2021209）；广州市科技计划项目（202002030031） |
|
| 摘要点击次数: 1951 |
| 全文下载次数: 602 |
| 中文摘要: |
| 目的 总结并评价儿少期头颈部交界性肿瘤125I放射性粒子植入方案的靶区与剂量设计。方法 选择2010年1月至2018年12月间于北京大学口腔医院就诊经单纯125I放射性粒子组织间植入近距离治疗或联合手术治疗的儿少期交界性肿瘤患者11例，以大体肿瘤靶区外扩0.5~1.0 cm为计划靶区，处方剂量80~120 Gy，活度为18.5 MBq，全麻下按治疗计划将125I放射性粒子植入靶区。术后进行随访，记录疗效及不良反应。评析粒子植入前、后剂量学参数以及局部控制率、客观缓解率和不良反应发生率。结果 11例儿少期患者粒子植入前、后剂量学参数差异无统计学意义（P>0.05）。随访33~131个月，中位时间48个月。局部控制率100%，完全缓解率71.4%，客观缓解率100%，急性不良反应率81.8%。结论 125I放射性粒子植入治疗儿少期头颈部交界瘤，在合理的靶区及剂量设计下，可获得满意的临床疗效且不良反应较低，是一种可行的治疗手段。 |
| 英文摘要: |
| Objective To summarize and evaluate the target and dose design of 125I seed brachytherapy treatment plan of pediatric borderline tumor in head neck region. Methods Eleven patients underwent definitive 125I brachytherapy or combined with surgery in Peking University Hospital of Stomatology from January 2010 to December 2018 were retrospective analyzed. The target region was set by extending the tumor gross region by 0.5 to 1.0 cm. The prescription dose and activity ranged from 80 to 120 Gy and 18.5 MBq, respectively. The treatments were performed according to the plan under general anesthesia. Response and toxic reaction were recorded during follow-up. The preoperative and postoperative dosimetric results were compared; and the local control rate, objective response rate, complete response rate and acute toxic reaction rate were calculated. Results There was no statistically significant difference between preoperative and postoperative dosimetric results (P>0.05). The follow-up time ranged from 33 to 131 months, with a median of 48 months. The local control rate, objective response rate, complete response rate and acute toxic reaction rate were 100%, 100%,71.4% and 81.8%, respectively. Conclusions Under well-designed target and dose, 125I brachytherapy for treatment of pediatric borderline tumor in head neck region would bring ideal therapeutic and toxic outcomes, and could be regarded as a feasible therapy. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|